In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

King's College London

Division of University of London
http://www.kcl.ac.uk

Latest From King's College London

Finance Watch: Q1 Numbers Suggest A Brisk VC Deal Pace For Cell And Gene Therapies In 2019

An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.

Financing Regenerative Medicine

Start-Up Quarterly Statistics, Q4 2014

In Q4 2014 start-ups raised $1.5 billion, a new record. Several companies penned alliances with tech transfer entities; eight start-ups were acquired.

BioPharmaceutical Medical Device

Bristol Takes Option To Buy Danish Biotech, Increases Efforts In Fibrosis

Bristol can buy out Galecto any time up to 60 days after the completion of a Phase Ib study of an inhalable drug candidate for idiopathic pulmonary fibrosis. The deal follows just weeks after FDA approved the first two drug therapies for IPF.

BioPharmaceutical United States

Imanova Ltd.

Drug development is a costly and challenging process, with a high attrition rate. Imanova Ltd., based in London, is a translational imaging center with an aim to improve success rates by using molecular imaging techniques to provide early information in clinical studies to support development decisions.

BioPharmaceutical Research and Development Strategies
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register